Article

16-Year Trends in the Infection Burden for Pacemakers and Implantable Cardioverter-Defibrillators in the United States

Division of Cardiology, Department of Medicine, Thomas Jefferson University Hospital, 925 Chestnut Street, Philadelphia, PA 19107, USA.
Journal of the American College of Cardiology (Impact Factor: 15.34). 08/2011; 58(10):1001-6. DOI: 10.1016/j.jacc.2011.04.033
Source: PubMed

ABSTRACT We analyzed the infection burden associated with the implantation of cardiac implantable electrophysiological devices (CIEDs) in the United States for the years 1993 to 2008.
Recent data suggest that the rate of infection following CIED implantation may be increasing.
The Nationwide Inpatient Sample (NIS) discharge records were queried between 1993 and 2008 using the 9th Revision of the International Classification of Diseases (ICD-9-CM). CIED infection was defined as either: 1) ICD-9 code for device-related infection (996.61) and any CIED procedure or removal code; or 2) CIED procedure code along with systemic infection. Patient health profile was evaluated by coding for renal failure, heart failure, respiratory failure, and diabetes mellitus. The infection burden and patient health profile were calculated for each year, and linear regression was used to test for changes over time.
During the study period (1993 to 2008), the incidence of CIED infection was 1.61%. The annual rate of infections remained constant until 2004, when a marked increase was observed, which coincided with an increase in the incidence of major comorbidities. This was associated with a marked increase in mortality and in-hospital financial charges.
The infection burden associated with CIED implantation is increasing over time and is associated with prolonged hospital stays and high financial costs.

Download full-text

Full-text

Available from: Behzad Pavri, Aug 24, 2015
0 Followers
 · 
156 Views
  • Source
    • "The number of implanted cardiac implantable electronic devices (CIED) has increased over the recent years [1]. This trend is caused by a wider range of indications [2] [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Methods. 17 physicians, experienced in transvenous lead removal, performed a lead extraction manoeuvre of an ICD lead on a torso phantom. They were advised to stop traction only when further traction would be considered as harmful to the patient or when-based on their experience-a change in the extraction strategy was indicated. Traction forces were recorded with a digital precision gauge. Results. Median traction forces on the endocardium were 10.9 N (range from 3.0 N to 24.7 N and interquartile range from 7.9 to 15.3). Forces applied to the proximal end were estimated to be 10% higher than those measured at the tip of the lead due to a friction loss. Conclusion. A traction force of around 11 N is typically exerted during standard transvenous extraction of ICD leads. A traction threshold for a safe procedure derived from a pool of experienced extractionists may be helpful for the development of required adequate simulator trainings.
    BioMed Research International 05/2014; 2014:183483. DOI:10.1155/2014/183483 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Au cours des dernières décennies, l’endocardite infectieuse a connu des bouleversements épidémiologiques, diagnostiques et thérapeutiques. Elle est devenue une maladie de la personne âgée, souvent sans valvulopathie identifiée. Elle est de plus en plus souvent associée aux soins intra- et extrahospitaliers. L’incidence des infections à staphylocoque a été multipliée par deux. L’échocardiographie et les hémocultures demeurent les examens diagnostiques essentiels. Cependant, de nouveaux outils microbiologiques sont en cours d’évaluation. Des examens d’imagerie (imagerie par résonance magnétique, tomographie par émission de positons) permettent de diagnostiquer très fréquemment des métastases septiques cliniquement silencieuses. Cependant, l’impact de ces examens sur la prise en charge et sur le devenir reste à déterminer. La chirurgie des endocardites du coeur gauche est réalisée dans 50%des cas à la phase active, et il est établi qu’elle améliore le pronostic. À côté des indications chirurgicales reconnues que sont une insuffisance cardiaque sévère, une extension paravalvulaire ou des embolies multiples, un essai randomisé récent suggère qu’une chirurgie très précoce en cas d’atteinte valvulaire avec des végétations supérieures à 10 mm diminue l’incidence des accidents emboliques. Les complications neurologiques constituent la complication extracardiaque la plus fréquente. Elles sont un motif fréquent d’admission en réanimation et sont associées à un mauvais pronostic. En l’absence d’hémorragie cérébrale importante ou de lésions ischémiques à l’origine d’une défaillance neurologique sévère, la chirurgie peut être réalisée avec un risque d’aggravation neurologique postopératoire faible. Les schémas antibiotiques ont été actualisés dans de nombreuses recommandations. L’antibioprophylaxie a vu ses indications considérablement réduites. L’endocardite demeure associée à une mortalité hospitalière élevée comprise entre 10 et 40 %.
    Réanimation 01/2012; 22(2). DOI:10.1007/s13546-012-0539-9
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The implantation of cardiac implantable electronic devices (CIED) to prevent sudden cardiac death, ameliorate chronic congestive heart failure, and correct bradycardia has grown rapidly in the past decade. Bacterial infection of the device hardware (pacemaker or implantable cardioverter defibrillator [ICD] pulse generator, and intravascular wires or leads), including the tissue pocket, is rising at an even faster rate. The source infection inoculation typically occurs at the time the device is implanted, revised, or when a device generator replacement occurs. This risk is clearly related to patient and procedure-specific factors, and is reviewed in the present paper. Prophylactic preoperative antibiotics, strict sterile technique, and limiting procedure times may reduce infection risk. A novel Antibacterial Envelope (AIGISRx ® , TYRX Inc., Monmouth Junction, NJ, USA) that is directly implanted with the device generator to provide site-specific therapy could significantly lower infection risk in certain high-risk cases. This may potentially reduce inpatient mortality related to endocarditis and sepsis, and lower healthcare costs related to CIED extraction and re-implantation, which can exceed $1 million per case.
    10/2011; 1(1). DOI:10.1007/s13556-011-0003-6
Show more